FDA approves Mylan's generic Sular

PITTSBURGH The Food and Drug Administration has granted final approval to a Mylan hypertension drug, the company has announced.

The drug, nisoldipine extended release, is a generic version of Sciele Pharma’s drug Sular ER. The drug will be available in 20 mg, 30 mg and 40 mg strengths.

Sular had sales of about $94 million in the year ended March 31, according to Mylan. The ‘741 patent that protected Sular expired June 8.